{"id":"ec-to-docetaxel-or-paclitaxel","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Neutropenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"10-30","effect":"Thrombocytopenia"},{"rate":"50-70","effect":"Nausea/vomiting"},{"rate":"60-90","effect":"Alopecia"},{"rate":"10-30","effect":"Peripheral neuropathy"},{"rate":"50-70","effect":"Fatigue"},{"rate":"20-40","effect":"Mucositis"},{"rate":"1-5","effect":"Cardiotoxicity"}]},"_chembl":{"chemblId":"CHEMBL92","moleculeType":"Small molecule","molecularWeight":"807.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a multi-agent chemotherapy combination where epirubicin and cyclophosphamide (EC) are administered first as DNA-damaging agents, followed by taxane chemotherapy (docetaxel or paclitaxel) which stabilizes microtubules and prevents cell division. The sequential approach is designed to maximize efficacy while managing cumulative toxicity, commonly used in breast cancer treatment.","oneSentence":"EC (epirubicin/cyclophosphamide) followed by docetaxel or paclitaxel is a sequential chemotherapy regimen that damages cancer cell DNA and disrupts microtubule function to inhibit tumor growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:28.644Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (likely early-stage or locally advanced, based on typical EC→taxane use)"}]},"trialDetails":[{"nctId":"NCT04310007","phase":"PHASE2","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-13","conditions":"Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":117},{"nctId":"NCT04872985","phase":"PHASE2","title":"Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-04-20","conditions":"Breast Cancer, Hormone-receptor Positive Breast Cancer","enrollment":140},{"nctId":"NCT07317778","phase":"PHASE2","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-15","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer","enrollment":249},{"nctId":"NCT04193059","phase":"PHASE3","title":"Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2019-12-20","conditions":"Breast Cancer","enrollment":1560},{"nctId":"NCT03201861","phase":"PHASE3","title":"Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2017-07-27","conditions":"Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Duct Carcinoma of Breast","enrollment":762},{"nctId":"NCT03609047","phase":"PHASE2","title":"Adjuvant Palbociclib in Elderly Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2019-06-14","conditions":"Breast Cancer Stage II, Breast Cancer Stage III","enrollment":366},{"nctId":"NCT01966471","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-31","conditions":"Breast Cancer","enrollment":1846},{"nctId":"NCT03085368","phase":"PHASE2, PHASE3","title":"A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-03-01","conditions":"HER2-positive Breast Cancer","enrollment":482},{"nctId":"NCT01917578","phase":"PHASE3","title":"Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2008-08","conditions":"Breast Cancer","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":42414,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Taxol"],"phase":"phase_3","status":"active","brandName":"EC to docetaxel or paclitaxel","genericName":"EC to docetaxel or paclitaxel","companyName":"RenJi Hospital","companyId":"renji-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EC (epirubicin/cyclophosphamide) followed by docetaxel or paclitaxel is a sequential chemotherapy regimen that damages cancer cell DNA and disrupts microtubule function to inhibit tumor growth. Used for Breast cancer (likely early-stage or locally advanced, based on typical EC→taxane use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}